In a filing, Alnylam Pharmaceuticals Inc revealed its CMO & EVP Dev & Med Affairs Garg Pushkal unloaded Company’s shares for reported $1.63 million on Mar 24 ’25. In the deal valued at $300.00 per share,5,445 shares were sold. As a result of this transaction, Garg Pushkal now holds 20,221 shares worth roughly $5.46 million.
Then, Garg Pushkal sold 4,321 shares, generating $1,231,485 in total proceeds. Upon selling the shares at $285.00, the CMO & EVP Dev & Med Affairs now owns 20,221 shares.
Before that, PYOTT DAVID E I sold 7,440 shares. Alnylam Pharmaceuticals Inc shares valued at $2,224,560 were divested by the Director at a price of $299.00 per share. As a result of the transaction, PYOTT DAVID E I now holds 136 shares, worth roughly $36694.16.
Redburn Atlantic initiated its Alnylam Pharmaceuticals Inc [ALNY] rating to a Buy in a research note published on March 31, 2025; the price target was $353. A number of analysts have revised their coverage, including JP Morgan’s analysts, who increased its forecast for the stock in late March from “a Neutral” to “an Overweight”. Wolfe Research also remained covering ALNY and has decreased its forecast on November 12, 2024 with a “an Underperform” recommendation from previously “Peer perform” rating. Scotiabank started covering the stock on October 16, 2024. It rated ALNY as “a Sector outperform”.
Price Performance Review of ALNY
On Tuesday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock fall -1.37% to $269.81. Over the last five days, the stock has gained 4.91%. Alnylam Pharmaceuticals Inc shares have risen nearly 14.66% since the year began. Nevertheless, the stocks have risen 79.50% over the past one year. While a 52-week high of $304.39 was reached on 03/24/25, a 52-week low of $144.73 was recorded on 04/09/25. SMA at 50 days reached $249.94, while 200 days put it at $259.06.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 266.13, which if violated will result in even more drops to 262.45. On the upside, there is a resistance level at 274.98. A further resistance level may holdings at 280.15. The Relative Strength Index (RSI) on the 14-day chart is 60.32, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 17.31, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 13.16%. Stochastics %K at 89.90% indicates the stock is a selling.
